What Adults Want From Eczema Treatment: Results From 697 Registry Participants
Dr. Arsy Editorial Team · November 9, 2026
Severity scores tell clinicians how much eczema is visible, but patients may define success differently. In a TREATgermany study, 697 adults with moderate-to-severe atopic dermatitis ranked treatment goals and reported how well those needs were met after two years of specialist care.[1]
Itch led the priorities
Being free of itching received high agreement from 97.8% of participants, followed by regaining control of the disease at 95.3% and relief from burning at 92.0%. The importance of itch relief was not strongly tied to baseline itch intensity, showing that even a symptom captured on one day may remain a central long-term concern.
Different groups emphasized different needs
Older adults placed more weight on safety and reduced dependence on care. Women more often emphasized psychosocial and appearance-related goals. Participants with lower educational status highlighted financial concerns, while adult-onset disease was associated with diagnostic certainty and control priorities.[1]
Patient-reported measures aligned more closely with benefit
After two years, 96.6% reported meaningful treatment benefit. POEM related more closely to perceived benefit than clinician-rated EASI or objective SCORAD. This does not make clinical examination unnecessary; it shows that combining perspectives gives a more complete assessment.
Build goals that can be revisited
- Which symptom most disrupts daily life?
- What would meaningful improvement look like in four months?
- Which risks, costs or monitoring requirements are unacceptable?
- Are sleep, work, exercise and relationships improving?
- Does the plan still fit the patient’s priorities?
Shared decisions become more concrete when a treatment target includes both disease signs and the outcome the patient actually values.[17][18][19][20][21]
Where moisturizer fits
Dr. Arsy Moisturizer #003 provides cosmetic hydration for dry, sensitive and eczema-prone skin. It was not tested in this study and should not be credited with the outcomes of systemic treatments, registries or health-service models.
Related evidence
- Minimal Disease Activity in Eczema: What the UP-TAINED Study Says About Quality of Life
- How Common Is Diagnosed Eczema in the US? Reading 5.57 Million Claims Carefully
- Eczema Targeted Therapy and Hospital Visits: What a 157,966-Adult Claims Study Found
- Oral Systemic Eczema Treatment in Practice: What AD-REAL Observed at 24 Weeks
- Related eczema research
- Related eczema research
Research and clinical references
- Patient treatment needs in atopic dermatitis: TREATgermany cohort.
- UP-TAINED minimal disease activity and quality of life.
- US atopic dermatitis prevalence estimates, 2019–2023.
- Targeted therapies, hospitalizations and emergency visits cohort.
- AD-REAL oral systemic treatment cohort.
- 48-week minimal disease activity real-world study.
- International TREAT Registry Taskforce core dataset.
- Treatment patterns and burden in moderate-to-severe atopic dermatitis.
- Real-world effectiveness of dupilumab: systematic review.
- Real-world upadacitinib effectiveness and safety.
- Baricitinib real-world atopic dermatitis study.
- Comparative effectiveness of systemic treatments network meta-analysis.
- Model-based meta-analysis of randomized eczema treatments.
- AAD adult systemic and phototherapy guideline.
- AAD adult topical therapy guideline.
- AAD pediatric management guideline.
- AAAAI/ACAAI atopic dermatitis guideline.
- Treat-to-target framework for atopic dermatitis.
- HOME core outcome set for atopic eczema.
- POEM validation and interpretability.
- RECAP long-term control instrument validation.
- Atopic dermatitis burden systematic review.
- Economic burden of atopic dermatitis in the United States.
- Quality of life measurement in atopic dermatitis.
Educational information only; not medical or financial advice. Cited researchers and organizations do not endorse Dr. Arsy products.